Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ColdZyme is a mouth spray designed to prevent and reduce the duration of the common cold by creating a protective barrier in the throat. Developed by the Swedish company Enzymatica, the formulation consists of glycerol and Atlantic cod trypsin (Penzyme). When applied to the pharyngeal mucosa, the glycerol creates a transient hyperosmotic barrier that traps viruses, while the trypsin enzyme cleaves viral surface proteins, thereby deactivating the virus and preventing it from binding to human cell receptors. It is primarily used as a prophylactic or at the onset of cold symptoms to mitigate viral load in the upper respiratory tract. In many jurisdictions, including the European Union, it is regulated as a Class III medical device.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ColdZyme.